Biologics News
AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets,) FDA Approved for the Treatment of Adult Patients with KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer who have Received Prior Systemic Therapy, Available at Biologics by McKesson
May 9, 2025
Cary, N.C. , May 9, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
VANRAFIA (atrasentan), FDA Approved for Adults with Immunoglobulin A Nephropathy, Available at Biologics by McKesson
April 3, 2025
CARY, N.C., April 3, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
GOMEKLI FDA Approved for Treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), Available at Biologics by McKesson
February 18, 2025
CARY, N.C., FEBRUARY 18, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
Romvimza (vimseltinib), FDA Approved for Treatment of Tenosynovial Giant Cell Tumor (TGCT), Available at Biologics by McKesson
February 17, 2025
CARY, N.C., February 17, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
REVUFORJ (revumenib), FDA Approved for Treatment of Patients with Acute Myeloid Leukemia and Acute Lymphoid Leukemia, Available at Biologics by McKesson
January 24, 2025
CARY, N.C., January 24, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected